|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation is the most common genetic alteration in thyroid cancer.
|
25266729 |
2014 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigates the expression of CYP24A1 and the effect of BRAF(V600E) on its expression in thyroid cancer.
|
24382015 |
2014 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation, RET rearrangements, and RAS mutations are the common genetic alterations in differentiated thyroid carcinomas derived from follicular thyroid cells.
|
27264674 |
2016 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
|
24617711 |
2014 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.
|
21185263 |
2011 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Epidermal growth factor receptor (EGFR) overexpression (EGFR-H) is implicated in thyroid carcinoma disease progression; however, the clinicopathologic significance of EGFR-H in tumors that harbor EGFR and/or v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)(V600E) mutations is unknown.
|
23746767 |
2013 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In many cancers, including thyroid cancer, B-Raf(V600E) appears to play a crucial role in cell proliferation, survival and de-differentiation.
|
19356676 |
2009 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In BRAF V600E mutated thyroid carcinomas, active ERK and active AKT kinase proteins were noted.
|
26403329 |
2015 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that generate RET/PTC and TRK oncogenes and with BRAF-V600E and RAS gene mutations.
|
23132790 |
2013 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results reveal a novel (V600E)BRAF-induced mechanism in thyroid tumours progression and provides a rationale for using the PLX4720 inhibitor to target (V600E)BRAF signalling to effectively control progression of thyroid cancer.
|
23435375 |
2013 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study also for the first time demonstrates an association of the BRAF(V600E) mutation with TC recurrence in pediatric patients.
|
26711586 |
2016 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
|
17387744 |
2007 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
When BRAF(V600E)-positive thyroid cancer cells were incubated with the specific BRAF inhibitor PLX4032, sensitivity to gefitinib was restored.
|
23559083 |
2013 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation was detected in the PTCs of the two patients with thyroid cancer.
|
29593792 |
2018 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E </span>mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers.
|
31529211 |
2019 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers.
|
17054470 |
2006 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
|
26384552 |
2015 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study was to determine whether combined detection of BRAF(V600E) mutation and methylation markers on FNABs could improve the diagnostic accuracy of thyroid cancer.
|
24588959 |
2014 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, our results suggest that the mTOR pathway could be a good target to enhance therapy effects in certain types of thyroid carcinoma, namely in those harboring the BRAF(V600E) mutation.
|
22549934 |
2012 |
|
rs121913377
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The inability of MEK and RAF inhibitors, U0126 and sorafenib, respectively, to block the mitochondrial localization of BRAF(V600E) has additional therapeutic implications for BRAF(V600E)-positive thyroid cancers.
|
20926530 |
2011 |